- Home
- CURR vs ASMB Comparison
CURR vs ASMB Comparison
Compare CURR & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CURR
- ASMB
- Stock Information
- Founded
- CURR 2013
- ASMB 2005
- Country
- CURR Singapore
- ASMB United States
- Employees
- CURR N/A
- ASMB N/A
- Industry
- CURR Business Services
- ASMB Biotechnology: Pharmaceutical Preparations
- Sector
- CURR Consumer Discretionary
- ASMB Health Care
- Exchange
- CURR Nasdaq
- ASMB Nasdaq
- Market Cap
- CURR 89.8M
- ASMB 97.8M
- IPO Year
- CURR N/A
- ASMB 2010
- Fundamental
- Price
- CURR $1.34
- ASMB $14.28
- Analyst Decision
- CURR
- ASMB Buy
- Analyst Count
- CURR 0
- ASMB 2
- Target Price
- CURR N/A
- ASMB $35.00
- AVG Volume (30 Days)
- CURR 10.5K
- ASMB 35.1K
- Earning Date
- CURR 02-11-2025
- ASMB 11-07-2024
- Dividend Yield
- CURR N/A
- ASMB N/A
- EPS Growth
- CURR N/A
- ASMB N/A
- EPS
- CURR N/A
- ASMB N/A
- Revenue
- CURR $55,500,917.00
- ASMB $28,326,000.00
- Revenue This Year
- CURR N/A
- ASMB $248.93
- Revenue Next Year
- CURR N/A
- ASMB $35.28
- P/E Ratio
- CURR N/A
- ASMB N/A
- Revenue Growth
- CURR N/A
- ASMB N/A
- 52 Week Low
- CURR $1.20
- ASMB $8.76
- 52 Week High
- CURR $5.74
- ASMB $19.93
- Technical
- Relative Strength Index (RSI)
- CURR N/A
- ASMB 36.57
- Support Level
- CURR N/A
- ASMB $14.75
- Resistance Level
- CURR N/A
- ASMB $15.94
- Average True Range (ATR)
- CURR 0.00
- ASMB 0.84
- MACD
- CURR 0.00
- ASMB -0.13
- Stochastic Oscillator
- CURR 0.00
- ASMB 4.00
About CURR Currenc Group Inc. Ordinary Shares
Currenc Group Inc is a fintech banking platform for e-wallets, financial institutions and merchants worldwide, delivering frictionless interoperable real-time fund transfers and instant messaging.
About ASMB Assembly Biosciences Inc.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two innovative platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.